Creabilis: Creabilis SA Completes EU FP7 Project And Selects Two Novel Drug Candidates For Further Development In Atopic Dermatitis And Psoriasis

Efficacy of novel kinase inhibitors further validates Creabilis low systemic exposure (LSE) technologyCanterbury, UK 9th December 2015 Creabilis, the dermatology company with an advanced targeted topical treatment in development for chronic pruritus (itch), today announces that two novel kinase inhibitor drugs for the treatment of atopic dermatitis and psoriasis, investigated with support...